Trial Profile
Phase II Trial of Investigational Agents to Modulate Intermediate Endpoint Biomarkers, Including Pulmonary Nodules, in Former and Current Smokers
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Curcumin (Primary) ; Omega-3-acid ethyl esters (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 21 Sep 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 21 Sep 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 17 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.